August 2, 2016 Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
July 26, 2016 Synthetic Biologics to Report Second Quarter 2016 Operational Highlights and Financial Results on August 3, 2016
July 12, 2016 Synthetic Biologics Announces Granting of European and U.S. Composition of Matter Patents for Ribaxamase
July 7, 2016 Synthetic Biologics Receives USAN Approval for Generic Name Ribaxamase for Phase 2 Drug Candidate SYN-004
July 6, 2016 Synthetic Biologics to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference
May 23, 2016 Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 17, 2016 Synthetic Biologics to Host Post-DDW 2016® Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
May 16, 2016 Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea
